Halows Co Ltd

Halows Co Ltd maintains a strong liquidity position with JPY 23.06 billion in cash and equivalents, which is a significant portion of its total assets of JPY 136.01 billion. The company's liquidity FPT (free cash flow to total liabilities) is supported by a current ratio of 0.83, indicating that it has sufficient short-term assets to cover its short-term liabilities, although it is slightly below the 1.0 threshold typically considered ideal for liquidity. In terms of profitability, Halows Co Ltd reports a return on equity (ROE) of 11.56% and a return on assets (ROA) of 6.61%. These figures suggest that the company is effectively utilizing its equity and assets to generate returns, which is in line with the industry's preferred metrics for profitability. The operating income of JPY 12.48 billion and net income of JPY 8.99 billion further support the company's strong profitability. The company's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification. This concentration may pose a risk if there are any regional economic downturns or changes in consumer behavior that affect the company's primary market. Looking at the growth trajectory, Halows Co Ltd has demonstrated a consistent revenue performance with a revenue of JPY 225.72 billion. The company's outlook for the current fiscal year is positive, with expected growth in revenue and profitability. The capital expenditure of JPY -12.93 billion indicates that the company is investing in its operations, which could support future growth. The risk assessment for Halows Co Ltd indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.14 suggests a conservative capital structure with minimal long-term debt. This indicates that the company is not heavily leveraged and has a low risk of financial distress. Recent events and filings for Halows Co Ltd do not show any significant changes or risks that would impact the company's operations or financial health. The company's financial statements and disclosures are consistent with its historical performance, and there are no indications of material adverse events that would affect its future outlook.